Abstract 112P
Background
Sarcopenia is known as a prognostic factor before surgery in esophageal carcinoma, however there is limited data about its exact value before neoadjuvant chemoradiotherapy. Therefore, the aim of present study was to evaluate sarcopenia prevalence before neoadjuvant chemoradiotherapy in patients with esophageal cancer and its relation with pathologic response to treatment.
Methods
In this retrospective study, all patients with esophageal cancer referred to Firoozgar hospital, Tehran during 2019 to 2021 who underwent neoadjuvant chemoradiotherapy followed by esophagectomy were included. Muscle mass was measured using a pre-treatment third lumbar vertebra CT-scan slice. Sarcopenia was internationally defined as skeletal muscle index of less than 39 cm2/m2 in women and less than 55 cm2/m2 in men. Association of sarcopenia with demographic and pathologic parameters and patients survival was statistically analyzed.
Results
Totally 67 patients including 34 men (50.7%) entered the study. Squamous cell carcinoma was the most common pathology in 91% of patients. Skeletal muscle index measurement was available in 58 patients in whom 56 (96.6%) showed sarcopenia. The mean of skeletal muscle index in men and women were 19.70 ± 8.01 and 19.63 ± 8.87 cm2/m2 respectively with no statistically significant difference. There was no significant correlation between sarcopenia with age, tumor pathology, tumor site or staging. The mean of skeletal muscle index in T2 tumors was significantly more than other stages (P=0.032). There was no significant relationship between sarcopenia and patients clinical outcome and survival. However skeletal muscle index was significantly higher in patients with complete pathologic response (P=0.004).
Conclusions
Frequency of pre-treatment sarcopenia was very high in patients with esophageal cancer. There was no association between sarcopenia before neoadjuvant chemoradiotherapy and the clinical outcome in patients with esophageal carcinoma but it affected complete pathologic response to therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Iran university of medical sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02